3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
16
Leukemia, Myelomonocytic, Acute
11
Leukemia, Monocytic, Acute
11
Leukemia, Megakaryoblastic, Acute
11
Leukemia, Erythroblastic, Acute
11
Breast Neoplasms
9
Congenital Abnormalities
8
Glioblastoma
7
Pancreatic Neoplasms
6
Recurrence
5
Leukemia, Myelomonocytic, Chronic
5
Leukemia, Eosinophilic, Acute
5
Leukemia, Basophilic, Acute
5
Leukemia
5
Gliosarcoma
5
Anemia, Refractory, with Excess of Blasts
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Carcinoma, Non-Small-Cell Lung
4
Brain Neoplasms
4
Blast Crisis
4
Urinary Bladder Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
3
Squamous Cell Carcinoma of Head and Neck
3
Multiple Myeloma
3
Lung Neoplasms
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Inflammatory Breast Neoplasms
3
Head and Neck Neoplasms
3
Breast Neoplasms, Male
3
Thyroid Neoplasms
2
Interventions
Cyclophosphamide
19
romidepsin
15
fludarabine phosphate
13
Whole-Body Irradiation
13
Peripheral Blood Stem Cell Transplantation
11
Mycophenolic Acid
11
Doxorubicin
11
Vincristine
10
Prednisone
10
Cyclosporine
10
10-propargyl-10-deazaaminopterin
10
Gemcitabine
8
Etoposide
8
Alemtuzumab
8
Bortezomib
6
Dexamethasone
5
Busulfan
5
Brentuximab Vedotin
5
mogamulizumab
4
denileukin diftitox
4
darinaparsin
4
Vitamin B 12
4
Nivolumab
4
Lenalidomide
4
Folic Acid
4
Carboplatin
4
carfilzomib
3
belinostat
3
Tacrolimus
3
Rituximab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, T-Cell, Peripheral
×
tipifarnib
×
Clear all
NCT02464228
2024-06-26
PTCL
Kura Oncology, Inc.
Phase 2
Completed
65 enrolled
16 charts